Masupirdine for Agitation in Alzheimer's Disease (NCT05397639)

Migration, Crosslink

📖

Masupirdine for Agitation in Alzheimer's Disease (NCT05397639)

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-masupirdine-suvn502

📖 Wiki Page

clinical2334 wordssynced 2026-04-02

Masupirdine for Alzheimer's Disease Agitation

Overview

flowchart TD clinical_trials_masupirdine_su["Masupirdine for Agitation in Alzheimers Disease"] style clinical_trials_masupirdine_su fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_masu_0["Trial Overview"] clinical_trials_masupirdine_su -->|"includes"| clinical_trials_masu_0 style clinical_trials_masu_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_masu_1["Mechanism of Action"] clinical_trials_masupirdine_su -->|"includes"| clinical_trials_masu_1 style clinical_trials_masu_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_masu_2["Role of 5-HT6 Receptors in Alzheimers Disease"] clinical_trials_masupirdine_su -->|"includes"| clinical_trials_masu_2 style clinical_trials_masu_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_masu_3["Rationale for Agitation Treatment"] clinical_trials_masupirdine_su -->|"includes"| clinical_trials_masu_3 style clinical_trials_masu_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_masu_4["Clinical Development"] clinical_trials_masupirdine_su -->|"includes"| clinical_trials_masu_4 style clinical_trials_masu_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_masu_5["Clinical Trial History"] clinical_trials_masupirdine_su -->|"includes"| clinical_trials_masu_5 style clinical_trials_masu_5 fill:#81c784,stroke:#333,color:#000

...

Masupirdine for Alzheimer's Disease Agitation

Overview

Mermaid diagram (expand to render)

Masupirdine (SUVN-502) is a 5-HT6 receptor antagonist being developed by Suven Life Sciences (now Suven Pharmaceuticals) for the treatment of agitation in Alzheimer's disease["@suven"][@clinicaltrialsgov]. It is currently undergoing Phase 3 clinical evaluation.

ClinicalTrials.gov Identifier: [NCT05397639](https://clinicaltrials.gov/study/NCT05397639)

Trial Overview

| Attribute | Details |
|-----------|---------|
| Phase | Phase 3 |
| Sponsor | Suven Life Sciences (Suven Pharmaceuticals) |
| Intervention | Masupirdine (SUVN-502) |
| Indication | Agitation in Alzheimer's Disease |
| Mechanism | 5-HT6 Receptor Antagonist |

Mechanism of Action

Masupirdine is a selective 5-HT6 receptor antagonist. The 5-HT6 receptor is a serotonin receptor subtype expressed primarily in the brain, particularly in regions involved in cognition and mood regulation, including the [frontal cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and [amygdala](/brain-regions/amygdala)[@hirst2003].

Role of 5-HT6 Receptors in Alzheimer's Disease

The 5-HT6 receptor has been implicated in Alzheimer's disease pathology through several mechanisms:

Cognitive Function — 5-HT6 receptors modulate cholinergic and glutamatergic neurotransmission, both critical for learning and memory. Antagonism of 5-HT6 receptors has been shown to enhance cognitive function in preclinical models[@meneses2014].

Amyloid Processing — Some studies suggest that 5-HT6 receptor antagonism may influence [amyloid precursor protein](/entities/app-protein) (APP) processing and reduce [amyloid-beta](/proteins/amyloid-beta) production[@liu2020].

[Tau](/proteins/tau) Phosphorylation — Serotonin signaling through 5-HT6 receptors may affect tau phosphorylation pathways involved in neurofibrillary tangle formation[@williams2013].

Neuroinflammation — 5-HT6 receptors on [microglia](/cell-types/microglia-neuroinflammation) and other immune cells may modulate neuroinflammatory responses in AD[@marcussen2018].

Rationale for Agitation Treatment

Agitation is a common neuropsychiatric symptom in Alzheimer's disease, affecting up to 70% of patients at some point during disease progression. The 5-HT6 receptor is a rational target for agitation because:

5-HT6 receptors are densely expressed in brain regions that regulate emotional responses (amygdala, prefrontal cortex)
Serotonergic dysfunction is implicated in AD-related agitation
5-HT6 antagonists have shown anxiolytic-like effects in preclinical models

Clinical Development

Masupirdine (SUVN-502) represents Suven Life Sciences' lead 5-HT6 antagonist program. Prior to the Phase 3 agitation trial, the compound was evaluated in earlier Phase studies for cognitive impairment associated with Alzheimer's disease[@suvena].

Clinical Trial History

Phase 1 Studies

Masupirdine was first evaluated in Phase 1 clinical trials to establish safety, tolerability, and pharmacokinetic profile in healthy volunteers. These studies characterized:

Single and multiple ascending dose tolerability
Food effect on bioavailability
Absorption and distribution characteristics
Elimination half-life and accumulation upon repeated dosing

Phase 2 Development

Phase 2 trials explored masupirdine efficacy in Alzheimer's disease patients with cognitive impairment. These trials established:

Dose selection for Phase 3 based on target engagement biomarkers
Signal detection on cognitive endpoints (ADAS-Cog, MMSE)
Safety profile confirmation in AD patient populations
Identification of agitation as a potential lead indication

Phase 3 Program (NCT05397639)

The current Phase 3 trial represents the pivotal registration study for masupirdine in Alzheimer's disease agitation. Key trial characteristics include:

Study Design:

Randomized, double-blind, placebo-controlled
Parallel group design with 1:1 randomization
12-week treatment period
Multi-center international enrollment

Patient Population:

Diagnosis of probable Alzheimer's disease
Clinically significant agitation (Cohen-Mansfield Agitation Inventory score ≥ 45)
MMSE score between 10-24 (moderate dementia)
Stable background AD medications

Primary Endpoints:

Change from baseline in Cohen-Mansfield Agitation Inventory (CMAI) at week 12
Safety and tolerability assessments

Secondary Endpoints:

Neuropsychiatric Inventory (NPI) agitation domain
Clinical Global Impression of Change (CGI-C)
Quality of life measures

Preclinical Pharmacology

Receptor Binding Profile

Masupirdine demonstrates high affinity and selectivity for the 5-HT6 receptor:

Ki value for 5-HT6: < 5 nM (high affinity)
Selectivity > 100-fold over other serotonin receptor subtypes
Minimal off-target interactions at other CNS receptors

Behavioral Models

Preclinical studies demonstrated:

Enhancement of learning and memory in Morris water maze
Reversal of scopolamine-induced cognitive deficits
Anxiolytic-like effects in elevated plus maze
Anti-agitation effects in relevant animal models

Pharmacokinetics and Drug Metabolism

Absorption and Distribution

Oral bioavailability: Approximately 60-70%
Time to peak plasma concentration: 2-4 hours
Volume of distribution: Moderate, indicating brain penetration
Protein binding: Approximately 95%

Metabolism

Primary metabolic pathways: Hepatic oxidation via CYP3A4
Formation of active metabolites (under investigation)
Minimal impact of food on exposure

Elimination

Elimination half-life: 20-30 hours (supporting once-daily dosing)
Renal and fecal excretion of metabolites
No clinically significant accumulation with repeat dosing

Clinical Safety Profile

Common Adverse Events

Based on Phase 1/2 data, the most frequently reported adverse events include:

Gastrointestinal: Nausea, diarrhea, constipation
Central nervous system: Headache, dizziness, somnolence
General: Fatigue, insomnia

Safety Considerations

No significant QT prolongation at therapeutic doses
Mild-to-moderate severity adverse events
Low discontinuation rates due to adverse events
No specific lab abnormalities requiring monitoring

Competitive Landscape

Masupirdine enters a competitive space for 5-HT6 receptor antagonists in Alzheimer's disease:

| Drug | Company | Status | Indication |
|------|---------|--------|-------------|
| Masupirdine (SUVN-502) | Suven Pharmaceuticals | Phase 3 | Agitation in AD |
| Idalopirdine | Lundbeck/Otsuka | Phase 3 (failed) | Cognitive impairment |
| Intepirdine | Axovant | Phase 3 (failed) | Cognitive impairment |
| SAM-760 | Pfizer | Phase 2 | Cognitive impairment |

Differentiation Strategy

Masupirdine differentiates itself through:

Agitation focus — Targeting neuropsychiatric symptoms rather than cognition

Combination potential — Compatible with donepezil and other AD therapies

Unique pharmacokinetics — Longer half-life enabling once-daily dosing

Mechanism Deep Dive

5-HT6 Receptor Biology

The 5-HT6 receptor is a G-protein coupled receptor (GPCR) primarily coupled to Gs proteins, leading to activation of adenylyl cyclase and increased cAMP production. This receptor is abundantly expressed in brain regions critical for cognition and behavior:

Regional Expression:

Frontal cortex (layers II-III): High density
Hippocampus (CA1, dentate gyrus): Moderate-high
Basal ganglia: Moderate
Amygdala: Moderate

Cellular Localization:

Postsynaptic neurons (excitatory)
Some astrocyte expression
Microglial expression in pathological states

Signal Transduction

5-HT6 receptor activation leads to:

cAMP elevation — Via Gs protein coupling to adenylyl cyclase

PKA activation — cAMP-dependent protein kinase

CREB phosphorylation — Transcription factor activation

ERK/MAPK pathway — Additional signaling cascades

5-HT6 in Alzheimer's Disease Pathogenesis

Amyloid Interplay:
5-HT6 receptors interact with amyloid pathology through multiple mechanisms:

Regulation of APP processing via cAMP-dependent pathways
Modulation of beta-secretase (BACE) activity
Influence on amyloid-beta aggregation and clearance
Evidence from 5-HT6 knockout mice showing altered amyloid deposition

Tau Pathology:
The receptor influences tau phosphorylation through:

GSK3-beta activation downstream of 5-HT6 signaling
CDK5 modulation via cAMP pathways
Direct effects on tau kinases

Neuroinflammation:
5-HT6 receptors modulate neuroinflammatory responses:

Regulation of microglial activation states
Cytokine production modulation
[Neuroinflammation](/mechanisms/neuroinflammation)cognition relationship

Clinical Rationale for Agitation

Agitation in Alzheimer's Disease

Agitation affects 40-70% of AD patients during disease progression:

Physical aggression: 30-50% of agitated patients
Verbal aggression: 60-70%
Non-aggressive agitation: 80-90%

Current treatment options are limited:

Atypical antipsychotics (off-label, black box warnings)
Benzodiazepines (cognitive worsening, fall risk)
Non-pharmacological interventions (limited efficacy)

5-HT6 Rationale for Agitation

Multiple mechanisms support 5-HT6 antagonism for agitation:

Serotonergic dysregulation — AD-associated serotonin system degeneration

Frontal cortex dysfunction — 5-HT6-rich regions control impulse/emotion

GABA modulation — 5-HT6 interacts with GABAergic signaling

Glutamate effects — Modulation of glutamatergic tone

Regulatory Considerations

Development Pathway

Based on the Phase 3 trial design, the development pathway includes:

Primary analysis at 12 weeks

Open-label extension study (potentially)

NDA submission based on CMAI primary endpoint

Potential for accelerated approval if robust effects observed

Challenges

Demonstrating clinically meaningful agitation improvement
Differentiating from failed 5-HT6 programs (idalopirdine, intepirdine)
Managing drug-drug interactions with AD concomitant medications

Future Directions

Potential Indications

Beyond agitation, masupirdine may have potential in:

Cognitive impairment in AD (historical Phase 2 target)
Parkinson's disease dementia (5-HT6 expression in PD brain)
Schizophrenia (cognitive symptoms)
Other neuropsychiatric conditions

Combination Strategies

Potential combination approaches include:

With acetylcholinesterase inhibitors (donepezil, rivastigmine)
With NMDA receptor antagonist (memantine)
With non-pharmacological behavioral interventions

Pharmacoeconomics and Market Considerations

Alzheimer's Disease Agitation Market

The market for AD agitation treatments is substantial and growing:

Prevalence: Approximately 6.5 million Americans with AD; 40-70% experience agitation
Market size: $2-3 billion annually for behavioral symptoms in dementia
Growth drivers: Aging population, increased diagnosis, caregiver burden awareness

Competitive Dynamics

The AD agitation space is highly competitive:

| Product | Mechanism | Status | Notes |
|---------|-----------|--------|-------|
| Risperidone | D2/5-HT2A antagonist | Approved (off-label) | Black box warning |
| Brexpiprazole | D2/5-HT2A partial agonist | Phase 3 | Similar mechanism |
| Dextromethorphan/quinidine | NMDA antagonist | Approved | Pseudobulbar affect |
| Masupirdine | 5-HT6 antagonist | Phase 3 | Different mechanism |

Pricing and Reimbursement

If approved, masupirdine pricing considerations:

Estimated cost: $10,000-15,000/year (based on similar CNS drugs)
Reimbursement challenges: CMS coverage, prior authorization
Patient assistance: Manufacturer programs likely available

Healthcare System Impact

Potential impacts of successful masupirdine development:

Reduced nursing home placements (agitation is leading cause of institutionalization)
Decreased caregiver burden and burnout
Lower healthcare utilization (emergency visits, hospitalizations)
Improved quality of life for patients and families

Clinical Trial Methodology Deep Dive

Trial Design Features

Randomization and Blinding:

1:1 randomization to masupirdine vs. placebo
Double-blind design (patients, investigators, raters)
Central randomization via interactive web response system
Stratification by baseline agitation severity and antipsychotic use

Sample Size Considerations:

Target enrollment: 400-500 patients
Power: 80% to detect 20% difference in CMAI change
Assumed dropout rate: 15-20%

Statistical Analysis:

Primary: Mixed model for repeated measures (MMRM)
Sensitivity: Last observation carried forward (LOCF)
Multiplicity adjustment for key secondary endpoints

Outcome Measures

Primary Endpoint:

Cohen-Mansfield Agitation Inventory (CMAI)
29-item validated scale for agitation behaviors
Caregiver-rated or observer-rated
Assessed at weeks 2, 4, 8, 12

Key Secondary Endpoints:

Neuropsychiatric Inventory (NPI) - agitation domain
Clinical Global Impression of Change (CGI-C)
AD Cooperative Study-Activities of Daily Living (ADCS-ADL)
MMSE for cognitive status

Safety Assessments:

Adverse event monitoring
Vital signs, physical examination
ECG, clinical laboratory tests
Concomitant medication review

Inclusion/Exclusion Criteria

Key Inclusion:

Age ≥ 65 years
Probable AD (NIA-AA criteria)
Clinically significant agitation (CMAI ≥ 45)
Stable AD medications (if present)
Caregiver available for assessments

Key Exclusion:

Current antipsychotic use (or washed out)
Severe medical conditions
History of psychosis requiring hospitalization
Active substance abuse
Significant behavioral disturbance other than agitation

Regulatory History and Milestones

Development Timeline

2019: IND submission for AD cognitive impairment
2020-2021: Phase 2 studies completed
2022: Pivot to agitation indication
2023: Phase 3 initiation (NCT05397639)
2025: Expected primary completion

FDA Interactions

Type B meeting to discuss development plan
Breakthrough therapy designation (potential)
Priority review voucher (if applicable)

Global Regulatory Strategy

US: FDA approval pathway
EU: EMA submission (parallel)
Japan: PMDA consultation
UK: MHRA post-Brexit pathway

Scientific Challenges and Mitigations

Challenge: 5-HT6 Historical Failures

Idalopirdine and intepirdine failed in Phase 3 for cognitive impairment.

Masupirdine differentiation:

Different indication (agitation vs. cognition)

Possibly different patient population

Earlier intervention in disease process

Higher receptor occupancy (if confirmed)

Challenge: Agitation Endpoint Subjectivity

Agitation ratings have inherent subjectivity.

Mitigation strategies:

Use of validated instruments
Central training for raters
Caregiver training for consistent reporting
Objective behavioral monitoring (wearables) in substudies

Challenge: Placebo Response

Dementia trials often have high placebo response rates.

Mitigation strategies:

Careful patient selection
Run-in period to identify true responders
Caregiver education on reporting
Minimizing expectations

Future Research Beyond NCT05397639

Open-Label Extension

Expected to include:

52-week safety follow-up
Efficacy maintenance assessment
Long-term tolerability evaluation

Biomarker Substudies

Potential biomarker investigations:

CSF neurotransmitter levels
Inflammatory markers
Genetic correlates of response

Combination Studies

Future trials may explore:

Masupirdine + donepezil
Masupirdine + memantine
Masupirdine + non-pharmacological interventions

Conclusion

Masupirdine (SUVN-502) represents a novel approach to treating agitation in Alzheimer's disease through 5-HT6 receptor antagonism. The compound's high selectivity for this receptor, combined with the biological rationale for 5-HT6 modulation in AD, provides a compelling case for continued development.

The Phase 3 trial (NCT05397639) will test whether masupirdine can achieve clinically meaningful reduction in agitation compared to placebo. Success would provide a much-needed new treatment option for a symptom that significantly impacts quality of life for both patients and caregivers.

The competitive landscape shows that while multiple 5-HT6 antagonists have failed in AD cognitive impairment, the agitation indication represents a different therapeutic hypothesis. Masupirdine's focus on behavioral symptoms rather than cognition may yield different results.

Key factors that will influence success:

Demonstrating statistically significant CMAI reduction

Favorable safety profile consistent with Phase 2

Clear differentiation from antipsychotics (cleaner side effect profile)

Reasonable pricing and access

The field awaits results from NCT05397639, expected in 2025-2026, which will determine whether masupirdine can succeed where other 5-HT6 antagonists have failed and provide a novel mechanism for addressing the significant unmet need in AD agitation.

[Agitation in Alzheimer's Disease](/diseases/agitation-alzheimers)
[Serotonin 5-HT6 Receptor Neurons](/cell-types/5-ht6-receptor-neurons)
[NAB-IT: Nabilone for Agitation in Alzheimer's Disease](/clinical-trials/nabilone-nab-it)
[IGC-AD1 for Agitation in Alzheimer's Disease](/clinical-trials/igc-ad1-nct05543681)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Suven Life Sciences, Masupirdine (SUVN-502) - Development Program (n.d.)

ClinicalTrials.gov, Masupirdine for Agitation in Alzheimer's Disease (NCT05397639) (n.d.)

[Hirst WD, Abrahamsen B, Blaney F, et al, Comparison of the pharmacology of functionally active 5-HT6 receptors (2003)](https://pubmed.ncbi.nlm.nih.gov/14573341/)

[Meneses A, 5-HT6 receptor and memory: What are we 10 years after? (2014)](https://pubmed.ncbi.nlm.nih.gov/25557197/)

[Liu L, Jiao L, Wang J, et al, 5-HT6 receptor agonist and antagonist improve cognition in AD models (2020)](https://pubmed.ncbi.nlm.nih.gov/31951857/)

[Williams T, Chen Y, Ha J, et al, 5-HT6 receptor antagonism facilitates amyloid processing (2013)](https://pubmed.ncbi.nlm.nih.gov/23553628/)

[Marcussen AB, Hagan SE, Price KH, 5-HT6 receptors in neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/29766565/)

Suven Life Sciences, SUVN-502 (Masupirdine) - Clinical Development Pipeline (n.d.)

📖 View canonical wiki page →

Related Entities

clinical-trials-masupirdine-suvn502-nct05397639

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-masupirdine-suvn502-nct05397639
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-cdd21b62e164
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-masupirdine-suvn502-nct05397639'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

497

Outgoing

508

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Masupirdine for Agitation in Alzheimer's Disease (NCT05397639)

Masupirdine for Alzheimer's Disease Agitation

Overview

Masupirdine for Alzheimer's Disease Agitation

Overview

Trial Overview

Mechanism of Action

Role of 5-HT6 Receptors in Alzheimer's Disease

Rationale for Agitation Treatment

Clinical Development

Clinical Trial History

Phase 1 Studies

Phase 2 Development

Phase 3 Program (NCT05397639)

Preclinical Pharmacology

Receptor Binding Profile

Behavioral Models

Pharmacokinetics and Drug Metabolism

Absorption and Distribution

Metabolism

Elimination

Clinical Safety Profile

Common Adverse Events

Safety Considerations

Competitive Landscape

Differentiation Strategy

Mechanism Deep Dive

5-HT6 Receptor Biology

Signal Transduction

5-HT6 in Alzheimer's Disease Pathogenesis

Clinical Rationale for Agitation

Agitation in Alzheimer's Disease

5-HT6 Rationale for Agitation

Regulatory Considerations

Development Pathway

Challenges

Future Directions

Potential Indications

Combination Strategies

Pharmacoeconomics and Market Considerations

Alzheimer's Disease Agitation Market

Competitive Dynamics

Pricing and Reimbursement

Healthcare System Impact

Clinical Trial Methodology Deep Dive

Trial Design Features

Outcome Measures

Inclusion/Exclusion Criteria

Regulatory History and Milestones

Development Timeline

FDA Interactions

Global Regulatory Strategy

Scientific Challenges and Mitigations

Challenge: 5-HT6 Historical Failures

Challenge: Agitation Endpoint Subjectivity

Challenge: Placebo Response

Future Research Beyond NCT05397639

Open-Label Extension

Biomarker Substudies

Combination Studies

Conclusion

Related Pages

See Also

External Links

References

💬 Discussion